SCHEMBL29948360

SCHEMBL29948360

C[C@@H](OC(=O)Nc1c(Br)nnn1C)c1ccccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 19/20 0.62
LPAR3 Q9UBY5 8/20 0.46
LPAR2 Q9HBW0 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23384065 1.00 LPAR1 (0.62) LPAR1LPAR3LPAR2
SCHEMBL29908077 0.88 LPAR1 (0.59) LPAR1LPAR3LPAR2
SCHEMBL29948416 0.86 LPAR1 (0.57) LPAR1LPAR3LPAR2
SCHEMBL23384396 0.86 LPAR1 (0.57) LPAR1LPAR3LPAR2
SCHEMBL23384213 0.85 LPAR1 (0.46) LPAR1LPAR3
SCHEMBL29948336 0.85 LPAR1 (0.46) LPAR1LPAR3
SCHEMBL23383983 0.83 LPAR1 (0.63) LPAR1LPAR3
SCHEMBL25955451 0.83 LPAR1 (0.58) LPAR1LPAR3LPAR2
SCHEMBL12989052 0.83 LPAR1 (0.73) LPAR1LPAR3LPAR2
SCHEMBL30005304 0.83 LPAR1 (0.73) LPAR1LPAR3LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2025-10-02 US disclosed
US-12139474-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-11-12 US disclosed
US-11999717-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-06-04 US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 US disclosed
US-20240002367-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2024-01-04 US disclosed
US-11702407-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-07-18 US disclosed
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 US disclosed
EP-4161936-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-04-12 EP disclosed
EP-4161641-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-04-12 EP disclosed
US-11584738-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-02-21 US disclosed
US-20230012262-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-01-12 US disclosed
US-11548871-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-01-10 US disclosed
EP-4058144-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF Gilead Sciences, Inc. (US) 2022-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702407-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885
US-11584738-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885
US-12139474-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885
US-11548871-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof LPAR3, LPAR1, LPAR2 LPAR1 2/4885LPAR3 1/4885LPAR2 3/4885
US-11999717-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof LPAR3, LPAR1, LPAR2 LPAR1 2/4885LPAR3 1/4885LPAR2 3/4885
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR3, LPAR1, LPAR2 LPAR1 2/4885LPAR3 1/4885LPAR2 3/4885
US-20240002367-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885
US-20230212151-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885
US-20230012262-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 4/4885LPAR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.